Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo

  • Thorsten Füreder1,
  • Thomas Wanek2,
  • Pamina Pflegerl3,
  • Agnes Jaeger-Lansky1,
  • Doris Hoeflmayer1,
  • Sabine Strommer1,
  • Claudia Kuntner2,
  • Markus Müller1,
  • Oliver Langer1, 2 and
  • Volker Wacheck1Email author
BMC Pharmacology201010(Suppl 1):A41

https://doi.org/10.1186/1471-2210-10-S1-A41

Published: 16 November 2010

Background

Gastric cancer at advanced stage of disease is a major health problem and the prognosis with the current therapeutic treatment strategies remains poor. PI3K/mTOR pathway mutations, especially PTEN, PI3K3C and AKT mutations and pS6 overexpression, are found frequently in gastric cancer patients and are linked with poor outcome. Thus, we evaluated the dual PI3K and mTOR inhibitor BEZ235 against gastric cancer in vitro and in vivo.

Materials and methods

Three gastric cancer cell lines (N87, MKN28 and MKN45) were treated with BEZ235 (20–80 nM) and assessed for cell viability, cell death and cell cycle distribution. PI3K/mTOR protein target modulation was measured by Western blotting. For in vivo studies athymic nude mice were inoculated with N87 or MKN45 cells bilaterally and treated daily with 20 or 40 mg/kg BEZ235. Tumor [18F]fluorothymidine (FLT) uptake was measured via small animal PET.

Results

In vitro, treatment of gastric cancer cells with 20–80 nM BEZ235 decreased cell growth in a dose-dependent manner in all cell lines tested (up to −70%). This anti-proliferative activity was linked with a G1 cell cycle arrest (up to 75%). No significant induction of apoptosis by BEZ235 was observed. On the molecular level, BEZ235 led to a decrease of phosphorylation of AKT and S6 protein. In vivo, treatment with 20 and 40 mg/kg BEZ235 resulted in a significant anti-tumor effect in a N87 gastric cancer xenograft mouse model. BEZ235 therapy had no anti-tumort effect on MKN45 xenografts despite similar potent PI3K/mTOR target inhibition by BEZ235 in both xenograft models. However, expression of the proliferation marker thymidinthymidine kinase 1 correlated with sensitivity to BEZ235 in vivo. In line, [18F]FLT uptake was significantly reduced only in the BEZ235-sensitive tumor xenograft model as measured by small animal PET.

Conclusions

In conclusion, our study shows that dual PI3K/mTOR inhibition by BEZ235 is a valuable target for gastric cancer therapy but is tumor model-dependent. Correlative studies with implementation of non-invasive imaging tools such as [18F]FLT PET might be a novel and promising strategy for optimizing clinical testing of dual PI3K/mTOR inhibitors.

Authors’ Affiliations

(1)
Department of Clinical Pharmacology, Medical University of Vienna
(2)
Health and Environment Department, Molecular Medicine, AIT Austrian Institute of Technology GmbH
(3)
Department of Pathology, Medical University of Vienna

Copyright

© Wacheck et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement